Based on an evaluation of current data on the business development to date and the expected further business performance of the PharmaSGP Group in the fourth quarter of 2020, which was completed on November 27, 2020, the Management Board of PharmaSGP Holding SE has come to the conclusion that the business development in the full year 2020 will be weaker than expected and that the previous forecast for the full year 2020 therefore cannot be maintained. Assuming that there will be no further comprehensive lockdown in the second half of 2020 in connection with the COVID-19 pandemic in the target markets of PharmaSGP and that product launches will contribute to growth as planned, the Management Board had previously forecast a further increase in revenue growth and the adjusted EBIT margin for the full year 2020 compared to the first half of 2020. The Management Board now anticipates revenue growth and an adjusted EBIT margin below the previous forecast. In view of the current situation, which is characterized by the COVID-19 pandemic, it is not yet possible to make a reliable estimate of revenue and earnings development for the fourth quarter and thus also for the concrete business development for the full year 2020.